Mineralys Therapeutics, Inc. MLYS Common stock, capital shares reserved for future issuance
Common stock, capital shares reserved for future issuance at other companies
Other financials
Where this comes from
Reported directly by Mineralys Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CommonStockCapitalSharesReservedForFutureIssuance.
The official record: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mineralys Therapeutics, Inc.'s common stock, capital shares reserved for future issuance.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mineralys Therapeutics, Inc.'s common stock, capital shares reserved for future issuance?
- Mineralys Therapeutics, Inc. (MLYS) reported common stock, capital shares reserved for future issuance of $14.15M in Q1 2026.
- How has Mineralys Therapeutics, Inc.'s common stock, capital shares reserved for future issuance changed year-over-year?
- Mineralys Therapeutics, Inc.'s common stock, capital shares reserved for future issuance increased by 20.5% year-over-year, from $11.74M to $14.15M.
- What is the long-term trend for Mineralys Therapeutics, Inc.'s common stock, capital shares reserved for future issuance?
- Over 2 years (2023 to 2025), Mineralys Therapeutics, Inc.'s common stock, capital shares reserved for future issuance has grown at a 30.3% compound annual growth rate (CAGR), from $6.14M to $10.42M.